Hyperhomocysteinemia: The independent risk factor of cardiovascular diseases
Abstract
Hyperhomocysteinemia (Hcy) is an independent risk factor for cardiovascular diseases (CVD) and associated with primary causes of mortality and morbidity throughout the world. Association between Hcy and CVD has been a question for biologists over the last five decades. The circulating levels of Hcy can be increased by defects in enzymes involved in the metabolism of several B and therefore for homocysteine. Although researchers have yielded conflicting findings on the link between homocysteine and CVD risk, but there is convincing evidence on link between B vitamin deficiencies and increased CVD risk. This review identifies the research conducted on this subject matter and provides a framework for the factors associated with Hcy and CVD.
Keywords: Hyperhomocysteinemia; CVD; Methionine; Homocysteine
Full Text:
PDFReferences
Danaei G, Singh GM, Paciorek CJ, Lin JK, Cowan MJ, et al. The global cardiovascular risk transition: associations of four metabolic risk factors with national income, urbanization, and Western diet in 1980 and 2008. Circulation, (2013); 127(14): 1493-1502.
Aanensen DM, Feil EJ, Holden MTG, Dordel J, Yeats CA, et al. Whole-Genome Sequencing for Routine Pathogen Surveillance in Public Health: a Population Snapshot of Invasive Staphylococcus aureus in Europe. mBio, (2016); 7(3): 1-16.
Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation, (2014); 129(3): 933-944.
Control CfD, Prevention. Million hearts: strategies to reduce the prevalence of leading cardiovascular disease risk factors–United States, 2011. MMWR Morbidity and mortality weekly report, (2011); 60(36): 1248.
Emamgholipour S, Sari AA, Pakdaman M, Geravandi S. Economic Burden of Cardiovascular Disease in the Southwest of Iran. International Cardiovascular Research Journal, (2018); 12(1): 6-12.
Margozzini P, Passi A, Kruk M, Danaei G. P3415 Will less developed countries be capable of giving high-quality universal coverage to cardiovascular disease survivors? Results from a national health survey, Chile ENS 2016–2017. European Heart Journal, (2019); 40(Supplement_1): 2035.
Recio C, Maione F, Iqbal AJ, Mascolo N, De Feo V. The potential therapeutic application of peptides and peptidomimetics in cardiovascular disease. Frontiers in pharmacology, (2017); 6(7): 526.
Hajar R. Risk factors for coronary artery disease: historical perspectives. Heart views: the official journal of the Gulf Heart Association, (2017); 18(3): 109.
Ni Y, Xue L, Zhu G, Chen Y. Serum Homocysteine, VEGF and TGF-β1 dynamic change in colorectal cancer patients prior and post-operation. Pteridines, (2019); 30(1): 121-125.
Lopes C. Hyperhomocysteinemia: How Does it Affect the Development of Cardiovas-cular Disease. International Archives of Cardiovascular Diseases, (2018); 2(008):1-12.
Hasan T, Arora R, Bansal AK, Bhattacharya R, Sharma GS, et al. Disturbed homocysteine metabolism is associated with cancer. Experimnental and molecular medicine(2019); 51 (2): 1-13.
Kim J, Kim H, Roh H, Kwon Y. Causes of hyperhomocysteinemia and its pathological significance. Archives of pharmacal research, (2018); 41(4): 372-383.
Belardo A, Gevi F, Zolla L. The concomitant lower concentrations of vitamins B6, B9 and B12 may cause methylation deficiency in autistic children. The Journal of nutritional biochemistry, (2019); 7038-46.
Gao L, Siu PM, Chan S-w, Lai CW. Cardiovascular protective effects of salvianic acid a on db/db mice with elevated homocysteine level. Oxidative medicine and cellular longevity, (2017); 2017.
McCully KS. Homocysteine, vitamins, and vascular disease prevention. The American journal of clinical nutrition, (2007); 86(5): 1563S-1568S.
Lee KW, Hill JS, Walley KR, Frohlich JJ. Relative value of multiple plasma biomarkers as risk factors for coronary artery disease and death in an angiography cohort. Cmaj, (2006); 174(4): 461-466.
Bostom AG, Silbershatz H, Rosenberg IH, Selhub J, D'Agostino RB, et al. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Archives of Internal Medicine, (1999); 159(10): 1077-1080.
Vrentzos GE, Papadakis JA, Malliaraki N, Zacharis EA, Mazokopakis E, et al. Diet, serum homocysteine levels and ischaemic heart disease in a Mediterranean population. British journal of nutrition, (2004); 91(6): 1013-1019.
Chrysant SG, Chrysant GS. The current status of homocysteine as a risk factor for cardiovascular disease: a mini review. Expert review of cardiovascular therapy, (2018); 16(8): 559-565.
Chua S, Wu CJ, Chang HW, Hang CL, Chen CJ, et al. Impact of elevated plasma total homocysteine concentration on coronary atherosclerosis in Chinese patients with acute myocardial infarction undergoing primary coronary intervention. International heart journal, (2005); 46(2): 181-193.
Potter K, Hankey GJ, Green DJ, Eikelboom J, Jamrozik K, et al. The effect of long-term homocysteine-lowering on carotid intima-media thickness and flow-mediated vasodilation in stroke patients: a randomized controlled trial and meta-analysis. BMC cardiovascular disorders, (2008); 8(1): 24.
Durga J, Bots ML, Schouten EG, Grobbee DE, Kok FJ, et al. Effect of 3 y of folic acid supplementation on the progression of carotid intima-media thickness and carotid arterial stiffness in older adults. The American journal of clinical nutrition, (2011); 93(5): 941-949.
Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37 485 individuals. Archives of Internal Medicine, (2010); 170(18): 1622-1631.
Myung S-K, Ju W, Cho B, Oh S-W, Park SM, et al. Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials. Bmj, (2013); 346f10.
Qin X, Huo Y, Xie D, Hou F, Xu X, et al. Homocysteine-lowering therapy with folic acid is effective in cardiovascular disease prevention in patients with kidney disease: a meta-analysis of randomized controlled trials. Clinical nutrition, (2013); 32(5): 722-727.
Peng H-y, Man C-f, Xu J, Fan Y. Elevated homocysteine levels and risk of cardiovascular and all-cause mortality: a meta-analysis of prospective studies. Journal of Zhejiang university-science B, (2015); 16(1): 78-86.
Andersson C, Lyass A, Larson MG, Spartano NL, Vita JA, et al. Physical activity measured by accelerometry and its associations with cardiac structure and vascular function in young and middle‐aged adults. Journal of the American Heart Association, (2015); 4(3): e001528.
Lietava J, Dukat A, Fodor G. Homocysteine Slovakia study: study design and occurrence of hyperhomocysteinaemia and other risk factors. Bratislavske lekarske listy, (2012); 113(2): 80-86.
Dwivedi M, Tripathi A, Shukla S, Khan S, Chauhan U. Homocysteine and cardiovascular disease. Biotechnology and Molecular Biology Reviews, (2011); 6(5): 101-107.
Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. Jama, (1995); 274(13): 1049-1057.
Scheer AS, Boushey RP, Liang S, Doucette S, O'Connor AM, et al. The long-term gastrointestinal functional outcomes following curative anterior resection in adults with rectal cancer: a systematic review and meta-analysis. Diseases of the colon & rectum, (2011); 54(12): 1589-1597.
Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Bmj, (2002); 325(7374): 1202.
Christen WG, Ajani UA, Glynn RJ, Hennekens CH. Blood levels of homocysteine and increased risks of cardiovascular disease: causal or casual? Archives of Internal Medicine, (2000); 160(4): 422-434.
Kaul S, Zadeh AA, Shah PK. Homocysteine hypothesis for atherothrombotic cardiovascular disease: not validated. Journal of the American College of Cardiology, (2006); 48(5): 914-923.
Hoss GRW, Poloni S, Blom HJ, Schwartz IVD. Three Main Causes of Homocystinuria: CBS, cblC and MTHFR Deficiency. What do they Have in Common? Journal of Inborn Errors of Metabolism and Screening, (2019); 7.
Wierzbicki AS. Homocysteine and cardiovascular disease: a review of the evidence. Diabetes and Vascular Disease Research, (2007); 4(2): 143-149.
Bree Ad, Verschuren WM, Blom HJ, Kromhout D. Lifestyle factors and plasma homocysteine concentrations in a general population sample. American journal of Epidemiology, (2001); 154(2): 150-154.
Ganji V, Kafai MR. Demographic, lifestyle, and health characteristics and serum B vitamin status are determinants of plasma total homocysteine concentration in the post-folic acid fortification period, 1999–2004. The Journal of nutrition, (2009); 139(2): 345-352.
Ciaccio M, Bivona G, Bellia C. Therapeutical approach to plasma homocysteine and cardiovascular risk reduction. Therapeutics and clinical risk management, (2008); 4(1): 219.
Ambrose JA, Bhullar AS. Inflammation and Thrombosis in Coronary Atherosclerosis: Pathophysiologic Mechanisms and Clinical Correlations. EMJ, (2019); 4(1): 71-78.
de Koning AL, Werstuck GH, Zhou J, Austin RC. Hyperhomocysteinemia and its role in the development of atherosclerosis. Clinical biochemistry, (2003); 36(6): 431-441.
Mikael LG, Genest Jr J, Rozen R. Elevated homocysteine reduces apolipoprotein AI expression in hyperhomocysteinemic mice and in males with coronary artery disease. Circulation research, (2006); 98(4): 564-571.
Liao D, Tan H, Hui R, Li Z, Jiang X, et al. Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein AI Protein synthesis and enhancing HDL cholesterol clearance. Circulation research, (2006); 99(6): 598-606.
Chwatko G, Boers GH, Strauss KA, Shih DM, Jakubowski H. Mutations in methylenetetrahydrofolate reductase or cystathionine β-syntase gene, or a high-methionine diet, increase homocysteine thiolactone levels in humans and mice. The FASEB Journal, (2007); 21(8): 1707-1713.
Lentz S. Mechanisms of homocysteine‐induced atherothrombosis. Journal of Thrombosis and Haemostasis, (2005); 3(8): 1646-1654.
Elmadfa I, Singer I. Vitamin B-12 and homocysteine status among vegetarians: a global perspective. The American journal of clinical nutrition, (2009); 89(5): 1693S-1698S.
Litchford M. Assessment: laboratory data. Krause's Food and Nutrition Therapy 12th ed Canada: Saunders Elsevier, (2008).
Waly MI, Ali A, Al-Nassri A, Al-Mukhaini M, Valliatte J, et al. Low nourishment of B-vitamins is associated with hyperhomocysteinemia and oxidative stress in newly diagnosed cardiac patients. Experimental Biology and Medicine, (2016); 241(1): 46-51.
Verhoef P, Van Vliet T, Olthof MR, Katan MB. A high-protein diet increases postprandial but not fasting plasma total homocysteine concentrations: a dietary controlled, crossover trial in healthy volunteers–. The American journal of clinical nutrition, (2005); 82(3): 553-558.
Tian T, Yang K-Q, Cui J-G, Zhou L-L, Zhou X-L. Folic acid supplementation for stroke prevention in patients with cardiovascular disease. The American journal of the medical sciences, (2017); 354(4): 379-387.
Mohammed ZCM, Biomarkers for the Prediction of Incident Coronary Heart Disease in the MESA Cohort: Johns Hopkins University, (2015).
Perna AF, Ingrosso Dm. Homocysteine and chronic kidney disease: an ongoing narrative. Springer, (2019).
An Y, Feng L, Zhang X, Wang Y, Wang Y, et al. Dietary intakes and biomarker patterns of folate, vitamin B 6, and vitamin B 12 can be associated with cognitive impairment by hypermethylation of redox-related genes NUDT15 and TXNRD1. Clinical epigenetics, (2019); 11(1): 139.
Collaboration HLT. Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. The American journal of clinical nutrition, (2005); 82(4): 806-812.
Trialists’Collaboration HL. Blood homocysteine lowering with folic acid based supplements: a systematic overview of the randomised trials. Netherland Journal of Medicine, (1998); 52S33.
Wang B, Wu H, Li Y, Ban Q, Huang X, et al. Effect of long-term low-dose folic acid supplementation on degree of total homocysteine-lowering: major effect modifiers. British journal of nutrition, (2018): 120(10): 1122-1130.
Martí‐Carvajal AJ, Sola I, Lathyris D, Dayer M. Homocysteine‐lowering interventions for preventing cardiovascular events. Cochrane Database of Systematic Reviews, (2017); (8).
Kumar A, Palfrey HA, Pathak R, Kadowitz PJ, Gettys TW, et al. The metabolism and significance of homocysteine in nutrition and health. Nutrition & metabolism, (2017); 14(1): 78.
Hennekens CH. Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. Circulation, (1998); 97(11): 1095-1102.
De Bacquer D, De Smedt D, Kotseva K, Jennings C, Wood D, et al. Incidence of cardiovascular events in patients with stabilized coronary heart disease: the EUROASPIRE IV follow-up study. European journal of epidemiology, (2019); 34(3): 247-258.
Corella D, Coltell O, Mattingley G, Sorlí JV, Ordovas JM. Utilizing nutritional genomics to tailor diets for the prevention of cardiovascular disease: a guide for upcoming studies and implementations. Expert review of molecular diagnostics, (2017); 17(5): 495-513.
DOI: http://dx.doi.org/10.62940/als.v8i1.959
Refbacks
- There are currently no refbacks.